心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Atherosclerosis：大剂量阿托伐他汀可降低血浆CRP水平

2013-01-22 Atherosclerosis CMT 高晓方 编译

阿托伐他汀血浆CRP水平
关注

　　美国学者的一项研究表明，80 mg/天阿托伐他汀可通过显著缩短中位C反应蛋白（CRP）血浆滞留时间降低血浆CRP水平。论文于发表于《动脉粥样硬化》[Atherosclerosis 2013；226（2）：466-470]。 　　此项随机、安慰剂对照、双盲、交叉研究共纳入8例混合性高脂血症患者（男性5例，绝经后女性3例）。安慰剂和阿托伐他汀（80 mg/天）治疗8

　　美国学者的一项研究表明，80 mg/天阿托伐他汀可通过显著缩短中位C反应蛋白（CRP）血浆滞留时间降低血浆CRP水平。论文于发表于《动脉粥样硬化》[Atherosclerosis 2013；226（2）：466-470]。

　　此项随机、安慰剂对照、双盲、交叉研究共纳入8例混合性高脂血症患者（男性5例，绝经后女性3例）。安慰剂和阿托伐他汀（80 mg/天）治疗8周后，受试者接受15小时氘化亮氨酸持续预输注。通过亲和层析从脂蛋白缺乏血浆中分离CRP。利用气相色谱-质谱确定同位素富集，并利用房室模型确定动力学参数。

　　结果显示，与安慰剂相比，阿托伐他汀使中位CRP池大小降低28.4%（13.31±3.78对10.26±3.93 mg；P=0.16），与中位CRP部分分解代谢率增加39.9%相关（0.34±0.06对0.50 ± 0.11/天；P=0.09），并未为显著影响中位CRP产生率（0.050±0.01对0.049±0.01 mg/kg/天P=0.78）。


Effects of atorvastatin on human C-reactive protein metabolism

Objective
Statins are known to reduce plasma C-reactive protein (CRP) concentrations. Our goal was to define the mechanisms by which CRP was reduced by maximal dose atorvastatin.
Methods
Eight subjects with combined hyperlipidemia (5 men and 3 postmenopausal women) were enrolled in a randomized, placebo-controlled double-blind, cross over study. Subjects underwent a 15-h primed-constant infusion with deuterated leucine after 8 weeks of placebo and 80 mg/day of atorvastatin. CRP was isolated from lipoprotein deficient plasma, (density > 1.21 g/ml) by affinity chromatography. Isotopic enrichment was determined by gas chromatography/mass spectrometry. Kinetic parameters were determined using compartmental modeling. Paired t test and Wilcoxon signed ranks test were used to compare differences between placebo and atorvastatin.
Results
Compared with placebo, atorvastatin decreased median CRP pool size by 28.4% (13.31 ± 3.78 vs 10.26 ± 3.93 mg; p = 0.16), associated with a median CRP fractional catabolic rate increase of 39.9% (0.34 ± 0.06 vs 0.50 ± 0.11 pools/day; p = 0.09), with no significant effect on median CRP production rate (0.050 ± 0.01 vs 0.049 ± 0.01 mg/kg/day; p = 0.78).
Conclusion
Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate.

    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
    2013-07-31 12498b37m72暂无昵称

    #Sclerosis#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
    2013-03-22 zhangph

    #CRP水平#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
    2013-01-24 rebeccajiejie

    #CRP#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
    2013-01-24 lsndxfj

    #ROS#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
    2013-01-24 ms7899726347904398

    #大剂量#

    0

相关资讯

术前高剂量他汀可预防PCI相关炎症和心肌损伤

　　2012年世界心脏病学大会于4月18～21日在阿联酋迪拜召开，会上公布了我国北京大学第三医院研究人员开展的一项研究。该研究表明，于经皮冠脉介入（PCI）术前给予48小时的阿托伐他汀80 mg治疗可抑制PCI相关炎症,且对心肌具有一定的保护作用；高剂量与低剂量的阿托伐他汀组在安全性方面没有差异。 　　研究中，86例行PCI的冠心病（CHD）患者被随机分为对照组(n=30)、低剂

SATURN 研究解读：阿托伐他汀征战动脉粥样硬化

专家解读SATURN 研究 征战动脉粥样硬化，阿托伐他汀再添新证   2011 年11 月15 日，美国AHA 年会上，SATURN（采用血管内超声研究冠脉粥样硬化：瑞舒伐他汀和阿托伐他汀的疗效比较）研究结果在最新揭晓的临床研究专场公布，并同期在《新英格兰医学杂志》在线发表。这项头对头、比较大剂量他汀对动脉粥样硬化斑块影响的临床试验为强化他汀治疗、逆转斑块的作用增添了新的有利证据，

FDA驳回阿托伐他汀/依折麦布复方片申请

 3月5日，FDA表示，暂时不会批准默克公司提交的低密度脂蛋白药物阿托伐他汀和依折麦布复方片新药申请（NDA）。FDA指出，经全面审查后，默克公司需要提交额外的数据，但没有明确是什么数据。默克公司发表声明称，其计划就该问题与FDA 进行进一步的沟通，他们将很快提交阿托伐他汀和依折麦布复方片的新数据。不同剂量的阿托伐他汀与依折麦布联合应用和阿托伐他汀/依折麦布单独应用试验研究正在进行中。

JACC：阿托伐他汀与新发糖尿病相关性受基线危险因素影响

　　美国学者的一项研究表明，在新发糖尿病（NOD）低风险（无或1项NOD危险因素）患者中，大剂量阿托伐他汀（80 mg/天）未升高NOD发病率，但在高风险（2—4项NOD危险因素）患者中则增加24%的NOD风险；研究进一步表明，80 mg阿托伐他汀可明显减少以上两种风险人群的心血管疾病事件（CV）。论文发表于《美国心脏病学会杂志》[J Am Coll&nbs

Circulation：服用6个月阿托伐他汀不减弱肌肉强度

      尽管医生经常声称，他汀类药引起肌痛，但在STOMP试验之前，临床试验并没有仔细观察过这些药物对肌肉功能的效应。STOMP试验由Beth Parker 博士（哈特福德医院）牵头，结果显示，6个月大剂量阿托伐他汀不削弱患者的肌肉强度，但确实会提高患者肌酸激酶水平，导致肌痛。该试验结果发表在2012年11月26日的在线《循环》杂志上[Circulation 20